Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.37 CAD
Change Today 0.00 / 0.00%
Volume 218.1K
TH On Other Exchanges
As of 4:15 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

theratechnologies inc (TH) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - C$2.72
52 Week Low
12/3/14 - C$0.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THERATECHNOLOGIES INC (TH)

Related News

No related news articles were found.

theratechnologies inc (TH) Related Businessweek News

No Related Businessweek News Found

theratechnologies inc (TH) Details

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs in metabolic disorders. The company’s lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. The company was founded in 1993 and is headquartered in Montreal, Canada.

19 Employees
Last Reported Date: 02/26/15
Founded in 1993

theratechnologies inc (TH) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$450.0K
Vice President of Finance
Total Annual Compensation: C$182.5K
Senior Vice President of Medical Affairs
Total Annual Compensation: C$270.0K
Senior Chief Commercial Officer and Senior Vi...
Total Annual Compensation: C$265.5K
Vice President of Legal Affairs and Corporate...
Total Annual Compensation: C$250.0K
Compensation as of Fiscal Year 2014.

theratechnologies inc (TH) Key Developments

COFEPRIS Approves Theratechnologies Inc.'s EGRIFTA

Theratechnologies Inc. announced that COFEPRIS, Mexico's health agency, has approved the 2mg/vial presentation of tesamorelin for the treatment of lipodystrophy. The company's partner, sanofi, will re-submit a file to COFEPRIS to seek approval of the 1mg/vial presentation of EGRIFTATM which is the one currently marketed in other territories. As was the case with Canada, the commercialization of EGRIFTATM in Mexico will be initiated upon obtaining approval of the 1mg/vial presentation.

Theratechnologies Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended May 31, 2015

Theratechnologies Inc. announced unaudited consolidated financial results for the second quarter and six months ended May 31, 2015. For the quarter, the company reported net profit of CAD 818,000 against CAD 1,007,000 a year ago. Adjusted EBITDA was CAD 1,885,000 against adjusted LBITDA of CAD 3,081,000 a year ago. Revenue was CAD 7,280,000 against CAD 2,393,000 a year ago. The significant improvement to the Adjusted EBITDA in 2015 is principally due to the changes in the company's business model after regaining the U.S. commercialization rights to EGRIFTATM in May 2014. For the six months, the company reported net loss of CAD 96,000 against CAD 2,527,000 a year ago. Adjusted EBITDA was CAD 1,633,000 against adjusted LBITDA of CAD 5,710,000 a year ago. Revenue was CAD 11,851,000 against CAD 4,065,000 a year ago. In the six-month period ended May 31, 2015, operating activities generated positive cash flow of CAD 1,826,000, a significant improvement over the comparable period of 2014 when cash flow from operating activities was negative CAD 5,779,000.

Theratechnologies Announces Availability of EGRIFTA

Theratechnologies Inc. has announced the availability of EGRIFTA, which is intended for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, in Canada. The first shipment of EGRIFTA was sent to McKesson Canada's specialty wholesale group, Theratechnologies' Canadian-based wholesaler, in order to fill its supply chain. In addition, the availability of EGRIFTA in Canada will also enable AOP Orphan Pharmaceutical in Vienna, Austria, Theratechnologies' European partner, to initiate named-patients sales programs in Europe. Indeed, it will be the Canadian presentation of EGRIFTA that will be distributed through Theratechnologies' European partner.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TH:CN C$2.37 CAD 0.00

TH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TH.
View Industry Companies

Industry Analysis


Industry Average

Valuation TH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book 16.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERATECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at